Search Result

Results for "

Racemic mixtures

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (1) Adrenergic Receptor (1) Angiotensin Receptor (1) Apoptosis (1) Bacterial (1) Biochemical Assay Reagents (1) CDK (1) CXCR (1) Cytochrome P450 (1) Drug Metabolite (1) Endogenous Metabolite (2) Enolase (1) Fungal (2) Histone Methyltransferase (1) Isotope-Labeled Compounds (4) Lipoxygenase (1) Mitochondrial Metabolism (2) nAChR (1) Opioid Receptor (3) Parasite (1) PPAR (1) RSV (1) Topoisomerase (2) TRP Channel (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Endocrinology (3) Infection (6) Inflammation/Immunology (6) Metabolic Disease (13) Neurological Disease (5)

By Targets:

5 alpha Reductase (1)

Adrenergic Receptor (1)

Angiotensin Receptor (1)

Apoptosis (1)

Bacterial (1)

Biochemical Assay Reagents (1)

CDK (1)

CXCR (1)

Cytochrome P450 (1)

Drug Metabolite (1)

Endogenous Metabolite (2)

Enolase (1)

Fungal (2)

Histone Methyltransferase (1)

Isotope-Labeled Compounds (4)

Lipoxygenase (1)

Mitochondrial Metabolism (2)

nAChR (1)

Opioid Receptor (3)

Parasite (1)

PPAR (1)

RSV (1)

Topoisomerase (2)

TRP Channel (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (3)

Endocrinology (3)

Infection (6)

Inflammation/Immunology (6)

Metabolic Disease (13)

Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145263A

VD2173 epimer-1	Others	Cancer
VD2173 epimer-1 is a racemic mixture of VD2173 (HY-145263) .

HY-118590

ICRF-193	Topoisomerase	Cancer
ICRF-193 is an TopoII inhibitor. (S,S)- and (R,R)-isomers ICRF-193 make up an racemic mixture, ICRF-196 (HY-118590A). ICRF-196 can be used for the research of cancer .

HY-10011B

(Rac)-SCH 563705	CXCR	Inflammation/Immunology Endocrinology
(Rac)-SCH 563705 is a racemic mixture of SCH 563705 (HY-10011). SCH 563705 (compound 16) is a potent and orally active CXCR2 and CXCR1 antagonist with IC₅₀ values of 1.3 nM and 7.3 nM and K_i values of 1 nM and 3 nM, respectively .

HY-116663

(±)20-HDHA (±)20-HDoHE	Endogenous Metabolite	Neurological Disease
(±)20-HDHA ((±)20-HDoHE) is a racemic mixture and is an autoxidation product of Docosahexaenoic acid (DHA). (±)20-HDHA is also formed by peroxidation process in human platelets and rat brain homogenate .

HY-Y1315

DL-Tartaric acid 1 Publications Verification	Others	Others
DL-Tartaric acid is a non-racemic mixture of L- and D-tartaric acids with antioxidant activities .

HY-110406A

(±)13-HpODE 13-Hydroperoxylinoleic acid; Linoleic acid 13-hydroperoxide	Others	Others
(±)13-HpODE (13-hydroperoxylinoleic acid) is a racemic mixture of hydroperoxides, which is produced by the oxidation of linoleic acid by lipoxygenase .

HY-120109

13-HODE methyl ester	Endogenous Metabolite	Cancer
13-HODE methyl ester, a racemic mixture of 13(R)-HODE methyl ester and 13(S)-HODE methyl ester, is a 15-lipoxygenase metabolite of Linoleic acid .

HY-118590A

ICRF-196	Topoisomerase	Cancer
ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193 (HY-118590). ICRF-193 is an TopoII inhibitor. ICRF-196 can be used for the research of cancer .

HY-130319A

9-HEPE	PPAR	Cardiovascular Disease Metabolic Disease
9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .

HY-B0399A

DL-Carnitine (±)-Carnitin	Mitochondrial Metabolism	Metabolic Disease
DL-Carnitine is a racemic mixture of L-Carnitine and D-Carnitine, regulates fatty acid transport in mitochondria, elevates serum carnitine fractions.

HY-B2236

DL-Lysine (±)-2,6-Diaminocaproic acid	Others	Metabolic Disease
DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins .

HY-B2236A

DL-Lysine monohydrate (±)-2,6-Diaminocaproic acid monohydrate	Others	Metabolic Disease
DL-Lysine monohydrate is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins .

HY-134818

ML-SI1 5 Publications Verification	TRP Channel	Neurological Disease
ML-SI1, a racemic mixture of diastereomers, is a TRPML inhibitor with an IC₅₀ value of 15 μM for TRPML1 .

HY-12993A

RSV604 racemate A-60444 racemate	RSV	Others
RSV604 (A-60444) racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.

HY-103019A

(±)-Enitociclib (±)-BAY-1251152; (±)-VIP152	CDK	Cancer
(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.

HY-100869B

*MM-589 (racemic* mixture ) (TFA)**	Histone Methyltransferase	Cancer
MM-589 (racemic mixture) TFA, is a racemic mixture of MM-589 TFA (HY-100869A). MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC₅₀ of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC₅₀ of 12.7 nM .

HY-I0635

(Rac)-Apremilast (Rac)-CC-10004	Others	Inflammation/Immunology
(Rac)-Apremilast ((Rac)-CC-10004) is the racemic mixture of Apremilast. (Rac)-Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis .

HY-W010143

(R,S)-Norcotinine (Rac)-Norcotinine	Drug Metabolite	Cardiovascular Disease
(R,S)-Norcotinine ((Rac)-Norcotinine) is the racemic mixture of Norcotinine. (R,S)-Norcotinine is a biomarker of secondhand smoke exposure and is associated with the toxic mechanisms of secondhand smoke on cardiovascular development .

HY-Y1315R

DL-Tartaric acid (Standard)	Others	Others
DL-Tartaric acid (Standard) is the analytical standard of DL-Tartaric acid. This product is intended for research and analytical applications. DL-Tartaric acid is a non-racemic mixture of L- and D-tartaric acids with antioxidant activities .

HY-130310B

(±)11-HEDE 11-hydroxy-12,14-Eicosadienoic acid	Others	Metabolic Disease
(±)11-HEDE is a racemic mixture of the monohydroxy fatty acids 11(S)-HEDE and 11(R)-HEDE. 11-HEDE is formed from eicosadienoic acid by cyclooxygenase (COX) and in macrophages.

HY-15997B

(±)-U-50488 hydrochloride (±)-Trans-(1R,2R)-U-50488 hydrochloride	Opioid Receptor	Neurological Disease
(±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrochloride is a selective κ opioid receptor (KOR) agonist .

HY-15997C

(±)-U-50488 hydrate hydrochloride (±)-Trans-(1R,2R)-U-50488 hydrate hydrochloride	Opioid Receptor	Neurological Disease
(±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrate hydrochloride is a selective κ opioid receptor (KOR) agonist .

HY-B0105B

(-)-Ketoconazole (-)-Ketoconazol; (-)-R 41400	Fungal	Infection Inflammation/Immunology
(-)-Ketoconazole ((-)-R 41400) is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole).

HY-B2236S

DL-Lysine-d4 dihydrochloride (±)-2,6-Diaminocaproic acid-d₄ dihydrochloride	Isotope-Labeled Compounds	Metabolic Disease
DL-Lysine-4,4,5,5-d₄ (dihydrochloride) is the deuterium labeled DL-Lysine. DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins[1].

HY-B0105BS

(-)-Ketoconazole-d3 (-)-Ketoconazol-d₃; (-)-R 41400-d₃	Fungal	Infection Inflammation/Immunology
(-)-Ketoconazole-d₃ is deuterium labeled (-)-Ketoconazole. (-)-Ketoconazole ((-)-R 41400) is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole).

HY-121987A

(±)15-HEDE	Lipoxygenase	Inflammation/Immunology
(±)15-HEDE is a racemic mixture of the monohydroxy fatty acids 15(R)-HEDE and 15(S)-HEDE. 15-HEDE is formed from eicosadienoic acid in macrophages. It inhibits 5-lipoxygenase (5-LO; IC₅₀=35 μM).

HY-B2236S3

DL-Lysine-15N2 hydrochloride (±)-2,6-Diaminocaproic acid-¹⁵N₂ hydrochloride	Isotope-Labeled Compounds	Metabolic Disease
DL-Lysine- ¹⁵N₂ hydrochloride ((±)-2,6-Diaminocaproic acid- ¹⁵N₂ hydrochloride) is ¹⁵N labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.

HY-B2236S1

DL-Lysine-13C6 hydrochloride (±)-2,6-Diaminocaproic acid-¹³C₆ hydrochloride	Isotope-Labeled Compounds	Metabolic Disease
DL-Lysine- ¹³C₆ hydrochloride ((±)-2,6-Diaminocaproic acid- ¹³C₆ hydrochloride) is ¹³C-labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.

HY-126108

(±)8-HEPE	Others	Metabolic Disease
(±)8-HEPE is produced by non-enzymatic oxidation of EPA. It contains equal amounts of (±)8-HEPE and 8(R)-HEPE. The ability of (±)8-HEPE to induce hatching of E. modestus and B. balanoides eggs is probably due to the presence of the 8(R) isomer within the racemic mixture.

HY-12364C

(+)-trans-C75 (+)-C75	Mitochondrial Metabolism	Others
(+)-trans-C75 ((+)-C75) is an enantiomer of C75 (HY-12364) (a fatty acid synthase inhibitor). (+)-trans-C75 is less potent than the racemic mixture or the (-) enantiomer in enhancing the cancer-killing ability of ionizing radiation. (+)-trans-C75 inhibits CPT1 and is an anorectic agent .

HY-118091

LY191704	5 alpha Reductase	Endocrinology
LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1 .

HY-P2834

Penicillin amidase, E. coli PGA	Biochemical Assay Reagents	Infection Cancer
Penicillin amidase (EC 3.5.1.11) (Penicillin acylase) is an enzyme that cleaves the acyl side chains of penicillins. Penicillin amidase can be used for the production of 6-aminopenicillanic acid. Penicillin amidase can also be used in the resolution of racemic mixtures, peptide synthesis, and synthesis of semi-synthetic β-lactam antibiotics .

HY-131904

POMHEX 2 Publications Verification	Enolase Apoptosis	Metabolic Disease Cancer
POMHEX, a racemic mixture and a cell-permeable pivaloyloxymethyl (POM) proagent of HEX, is a potent, ENO2-specific inhibitor of enolase. POMHEX exhibits low-nanomolar potency against ENO1-deleted cells in vitro and is capable of eradicating ENO1-deleted xenografted tumours in vivo. POMHEX is a potent glycolysis inhibitor .

HY-B0827A

(R)-Dinotefuran (R)-MTI-446	nAChR Parasite	Infection
(R)-Dinotefuran ((R)-MTI-446), a neonicotinoid pesticide, exhibits comparative insecticidal activities (1.7-2.4 times) to typical sucking pests Aphis gossypii and Apolygus lucorum compared to racemic mixtures by inhibiting nicotinic acetylcholine receptors. (R)-Dinotefuran has a good efficacy in controlling target pests while minimizing hazard to honeybees .

HY-137258

(±)-N-3-Benzylnirvanol	Cytochrome P450	Metabolic Disease
(±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with K_i values of 0.25 and 5.3 μM for CYP2C19, respectively .

HY-B2236S2

DL-Lysine-13C6,15N2 hydrochloride (±)-2,6-Diaminocaproic acid-¹³C₆,¹⁵N₂ hydrochloride	Isotope-Labeled Compounds	Metabolic Disease
DL-Lysine- ¹³C₆, ¹⁵N₂ hydrochloride ((±)-2,6-Diaminocaproic acid- ¹³C₆, ¹⁵N₂ hydrochloride) is ¹³C and ¹⁵N-labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.

HY-19202

rac-Olodanrigan rac-EMA401; rac-PD-126055; EMA400	Angiotensin Receptor	Neurological Disease
rac-Olodanrigan (rac-EMA401; EMA400) is a racemic mixture of the S-enantiomer (EMA401; HY-13106) and R-enantiomer (EMA402). rac-Olodanrigan is a potent and selective AT₂ receptor antagonist with IC₅₀s of 75.2 nM and 2918 nM for AT₂R and AT₁R, respectively. rac-Olodanrigan evokes dose-dependent relief of mechanical allodynia in the ipsilateral hind paws of rats with a chronic constriction injury (CCI) of the sciatic nerve .

HY-113764

N-Butanoyl-DL-homoserine lactone (Rac)-C4-HSL	Bacterial	Infection Inflammation/Immunology
N-Butanoyl-DL-homoserine lactone ((Rac)-C4-HSL) is a racemic mixture of N-Butanoyl-D-homoserine lactone and N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa .

HY-137390A

(3S,5R)-Fluvastatin potassium	Others	Cardiovascular Disease Metabolic Disease
(3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.

HY-15997

(-)-U-50488 hydrochloride (-)-Trans-(1S,2S)-U-50488 hydrochloride	Opioid Receptor	Infection Cancer
(-)-U-50488 hydrochloride ((-)-Trans-(1S,2S)-U-50488 hydrochloride) is a selective kappa-opioid receptor (KOR) agonist (b>K_d=2.2 nM) over μ-opioid receptor (MOR) (b>K_d=430 nM). (-)-U-50488 hydrochloride is a more active enantiomer than (+)?trans-(1R,2R) U-50488 (HY-15997A)?or the (±)?trans-racemic mixture U-50488 (HY-15997B). (-)-U-50488 hydrochloride has a potent and sustained anti-HIV effect in fected blood monocyte-derived macrophages (MDM) .

HY-132184

5,6-Epoxyeicosatrienoic acid 5,6-EET; (±)5,6-EpETrE	Adrenergic Receptor	Endocrinology
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone.

Cat. No.	Product Name	Category	Target	Chemical Structure